EFFECT OF CHRONIC TREATMENT WITH (+)-PHNO, A D(2)AGONIST IN MPTP-TREATED MONKEYS

被引:64
作者
GOMEZMANCILLA, B [1 ]
BEDARD, PJ [1 ]
机构
[1] UNIV LAVAL,FAC MED,DEPT PHARMACOL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA
关键词
D O I
10.1016/0014-4886(92)90125-A
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A group of four drug naive Macaca fascicularis were rendered parkinsonian with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and then treated chronically with (+)-PHNO, a potent D2 agonist. After several days, dyskinesia appeared in all animals. At this point, the daily dose of (+)-PHNO was replaced by a dose of the D1 agonist CY 208-243. The substitution by CY 208-243 reproduced the same dyskinesia observed with (+)-PHNO. The administration of the DA synthesis inhibitor AMPT (α-methyl-p-tyrosine methyl ester) blocked the dyskinetic and antiparkinsonian effect of (+)-PHNO, and those effects were reestablished by the addition of a subthreshold dose of CY 208-243. Our results show that a selective D2 agonist is capable of inducing dyskinesia and suggest some kind of cooperation between D1 and D2 receptors in the antiparkinsonian and dyskinetic effect produced by (+)-PHNO. © 1992.
引用
收藏
页码:185 / 188
页数:4
相关论文
共 30 条
[1]   DOPAMINE RECEPTOR CHANGES IN UNTREATED AND (+)-PHNO-TREATED MPTP PARKINSONIAN PRIMATES [J].
ALEXANDER, GM ;
BRAINARD, DL ;
GORDON, SW ;
HICHENS, M ;
GROTHUSEN, JR ;
SCHWARTZMAN, RJ .
BRAIN RESEARCH, 1991, 547 (02) :181-189
[2]   DOPAMINERGIC MECHANISMS IN HEMIPARKINSONIAN MONKEYS [J].
BARONE, P ;
BANKIEWICZ, KS ;
CORSINI, GU ;
KOPIN, IJ ;
CHASE, TN .
NEUROLOGY, 1987, 37 (10) :1592-1595
[3]   CHRONIC TREATMENT WITH L-DOPA, BUT NOT BROMOCRIPTINE INDUCES DYSKINESIA IN MPTP-PARKINSONIAN MONKEYS - CORRELATION WITH [H-3] SPIPERONE BINDING [J].
BEDARD, PJ ;
DIPAOLO, T ;
FALARDEAU, P ;
BOUCHER, R .
BRAIN RESEARCH, 1986, 379 (02) :294-299
[4]  
BEDARD PJ, 1990, IN PRESS CURRENT CON
[5]  
BEDARD PJ, 1990, DISORDERS MOVEMENT, P187
[6]   DIFFERENTIAL-EFFECTS OF D1 AND D2 AGONISTS IN MPTP-TREATED PRIMATES - FUNCTIONAL IMPLICATIONS FOR PARKINSONS-DISEASE [J].
BOYCE, S ;
RUPNIAK, NMJ ;
STEVENTON, MJ ;
IVERSEN, SD .
NEUROLOGY, 1990, 40 (06) :927-933
[7]   A PRIMATE MODEL OF PARKINSONISM - SELECTIVE DESTRUCTION OF DOPAMINERGIC-NEURONS IN THE PARS COMPACTA OF THE SUBSTANTIA NIGRA BY N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE [J].
BURNS, RS ;
CHIUEH, CC ;
MARKEY, SP ;
EBERT, MH ;
JACOBOWITZ, DM ;
KOPIN, IJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14) :4546-4550
[8]   SUSTAINED-RELEASE (+)-PHNO [MK-458 (HPMC)] IN THE TREATMENT OF PARKINSONS-DISEASE - EVIDENCE FOR TOLERANCE TO A SELECTIVE D2-RECEPTOR AGONIST ADMINISTERED AS A LONG-ACTING FORMULATION [J].
CEDARBAUM, JM ;
CLARK, M ;
TOY, LH ;
GREENPARSONS, A .
MOVEMENT DISORDERS, 1990, 5 (04) :298-303
[9]   THE ANTIPARKINSONIAN ACTIONS AND PHARMACOKINETICS OF TRANSDERMAL (+)-4-PROPYL-9-HYDROXYNAPHTHOXAZINE (+PHNO) - PRELIMINARY-RESULTS [J].
COLEMAN, RJ ;
LANGE, KW ;
QUINN, NP ;
LOPER, AE ;
BONDI, JV ;
HICHENS, M ;
STAHL, SM ;
MARSDEN, CD .
MOVEMENT DISORDERS, 1989, 4 (02) :129-138
[10]   AROMATIC AMINO ACIDS AND MODIFICATION OF PARKINSONISM [J].
COTZIAS, GC ;
VANWOERT, MH ;
SCHIFFER, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (07) :374-&